A

AVAX Technologies Inc
OTC:AVXT

Watchlist Manager
AVAX Technologies Inc
OTC:AVXT
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 6.9k USD

AVAX Technologies Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AVAX Technologies Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
AVAX Technologies Inc
OTC:AVXT
Revenue
$732k
CAGR 3-Years
-27%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

AVAX Technologies Inc
Glance View

Market Cap
6.9k USD
Industry
Biotechnology

AVAX Technologies, Inc. is an immuno-oncology company, which engages in the provision of development and commercialization of vaccine therapies and technologies for the treatment of cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 29 full-time employees. The firm is focused on developing and commercializing its Autologous Cell (AC) Vaccine Technology Platform for the treatment of cancer. The AC Vaccine is a platform technology, which allows a patient's immune system to recognize its own cancer cells as foreign through the process of haptenization, cell processing and regimen of administration. The firm has approximately two vaccines that have completed Phase II clinical trials, both designated with Orphan Drug Status. MVAX is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage IV melanoma patients with measurable metastasis. OVAX is the Company's post-surgical autologous cell vaccine for Stage III and IV ovarian cancer. The OVAX trial is a Phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients.

AVXT Intrinsic Value
Not Available
A

See Also

What is AVAX Technologies Inc's Revenue?
Revenue
732k USD

Based on the financial report for Sep 30, 2008, AVAX Technologies Inc's Revenue amounts to 732k USD.

What is AVAX Technologies Inc's Revenue growth rate?
Revenue CAGR 5Y
-10%

Over the last year, the Revenue growth was 42%. The average annual Revenue growth rates for AVAX Technologies Inc have been -27% over the past three years , -10% over the past five years .

Back to Top